Chelsea Therapeutics (NASDAQ:CHTP) left investors stunned today after taking a steep tumble. Shares dropped almost 30% after the Food and Drug Administration (FDA) posted briefing documents ahead of an advisory committee meeting for Chelsea's drug Northera. The meeting is scheduled for next week, but what did the market see in today's release? Analysts David Williamson and Max Macaluso discuss the details in the video below.

The top stock pick for 2014
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers